Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Exelixis licenses oncology compound from Insilico

by Rick Mullin
September 16, 2023 | A version of this story appeared in Volume 101, Issue 31

 

Insilico Medicine has licensed to Exelixis the rights to develop and commercialize a molecular inhibitor of ubiquitin specific peptidase 1 (USP1) for the treatment of BRCA-mutated tumors. Under the agreement, Exelixis gains rights to ISM3091 and other USP1-targeting compounds for an up-front payment of $80 million. Insilico says ISM3091 is the third clinical-stage program to emerge from its generative artificial intelligence platform for small-molecule drug discovery.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.